complete remission


Also found in: Acronyms.

complete remission

Complete response Oncology Disappearance of all signs and symptoms of disease–eg, cancer, multiple sclerosis, with normalization of all biochemical and radiologic parameters, as well as a negative repeat biopsy–pathologic remission. Cf Partial remission.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
The complete remission rate was 32% in patients who received 500 mg of ofatumumab and 50% in patients who received 1,000 mg of ofatumumab.
Patients have had some "pretty impressive regressions and long, complete remissions" on this combination, Warrell says.
These first-in-human data demonstrated the safety and tolerability of UCART19, resulting in an 83% complete remission rate across the adult and pediatric patient population.
The KEYNOTE-087 trial involved 210 patients and the drug had an overall response rate of 69% with a complete remission rate of 22% and a partial remission rate of 47%.
pylon led to complete remission of lymphoma in seven patients and to partial remission in one patient.
Three of the women (12 percent) went into complete remission after getting this drug for up to 15 months.
There will be a primary analysis to determine complete remission at week 24 (confirmed at 26 weeks) and various secondary analyses at both 24 and 48 weeks which include biomarkers and markers of non-renal lupus.
In the May 16 NEW ENGLAND JOURNAL OF MEDICINE, the group reports that while tretinoin failed to benefit two patients, it caused complete remission in the other nine by prompting their immature -- and otherwise immortal -- leukemic white cells to finish developing and die off after a normal white-cell life span.
Out of the 12 patients, ten were evaluable with four showing a response, and three out of the four were complete responders and therefore reached the clinical endpoint of complete remission after only one cycle of therapy.
The researchers report that nine of the treated individuals improved; five experienced a complete remission of their major metastatic tumor.
As in AURA, the study population will be comprised of patients with biopsy-proven active LN who will be evaluated on the primary efficacy endpoint of complete remission, or renal response, at 52 weeks.
The product is intended to improve overall survival in patients with relapsed platinum-sensitive epithelial ovarian cancer, who enter a second complete remission.

Full browser ?